View ValuationMicroPort CardioFlow Medtech 将来の成長Future 基準チェック /56MicroPort CardioFlow Medtech利益と収益がそれぞれ年間104.9%と24.7%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に1.7% 111.1%なると予測されています。主要情報104.9%収益成長率111.06%EPS成長率Medical Equipment 収益成長16.1%収益成長率24.7%将来の株主資本利益率1.70%アナリストカバレッジLow最終更新日18 Dec 2024今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Mar 31MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 04, 2026MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 04, 2026. Location: no.501 niudun road, pudong new district, shanghai, Chinaお知らせ • Mar 18MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2025 Results on Mar 30, 2026MicroPort CardioFlow Medtech Corporation announced that they will report fiscal year 2025 results on Mar 30, 2026お知らせ • Aug 15MicroPort CardioFlow Medtech Corporation to Report First Half, 2025 Results on Aug 28, 2025MicroPort CardioFlow Medtech Corporation announced that they will report first half, 2025 results on Aug 28, 2025お知らせ • Jun 27MicroPort CardioFlow Medtech Corporation Announces Board Changes, Effective June 27, 2025MicroPort CardioFlow Medtech Corporation announced that Dr. Ding Jiandong (Dr. Ding) retired as an independent non-executive Director with effect from the conclusion of the AGM and did not offer himself for re-election at the AGM as disclosed in the Circular. Accordingly, Dr. Ding ceased to act as a member of each of the audit committee (the Audit Committee) and nomination committee of the Company (the Nomination Committee) with effect from the conclusion of the AGM. Dr. Ding has confirmed that he has no disagreement with the Board and there is no matter relating to his retirement that needs to be brought to the attention of the Shareholders or the Stock Exchange. The Board announced that Dr. Hu Bingshan (Dr. Hu) has been appointed as an independent non-executive Director and a member of each of the Audit Committee and Nomination Committee, with effect from June 27, 2025 following the retirement of Dr. Ding. The biographical details of Dr. Hu are set out: Dr. Hu, aged 43, has successively served as associate professor and professor at the University of Shanghai for Science and Technology since November 2016. His main research field is rehabilitation and nursing robotics. From October 2010 to November 2016, Dr. Hu worked as a space robotics systems engineer at the Shanghai Aerospace System Engineering Institute in the China Aerospace Science and Technology Corporation. In 2015, he also served as a visiting scholar at the University of Hamburg in Germany. Dr. Hu serves as a committee member for the Sports Health and Industry Promotion Committee of China Association of Rehabilitation Medicine and other relevant academic organizations. He received the First Prize and the Second Prize of Science and Technology from the China Association of Rehabilitation Medicine in October 2023 and in September 2024, respectively. Dr. Hu has published more than 50 papers in internationally recognized journals or academic conferences. He is also an inventor or co-inventor of more than 70 Chinese and overseas patents. Dr. Hu received his bachelor's degree in electrical engineering and automation and his master's degree in power electronics and electric drives from Harbin University of Science and Technology in July 2003 and April 2006, respectively, and obtained his Ph.D. in mechatronic engineering from Shanghai Jiao Tong University in December 2010. Dr. Hu shall only hold office until the next annual general meeting of the Company and will be eligible for and subject to re-election at such meeting in accordance with the articles of association of the Company.お知らせ • Mar 28MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 27, 2025MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 27, 2025. Location: no. 1661 zhangdong road, zhangjiang hi-tech park, pudong new district, shanghai Chinaお知らせ • Mar 17MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2024 Results on Mar 27, 2025MicroPort CardioFlow Medtech Corporation announced that they will report fiscal year 2024 results at 4:00 PM, China Standard Time on Mar 27, 2025お知らせ • Aug 15MicroPort CardioFlow Medtech Corporation to Report First Half, 2024 Results on Aug 28, 2024MicroPort CardioFlow Medtech Corporation announced that they will report first half, 2024 results on Aug 28, 2024お知らせ • Mar 29MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 26, 2024MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 26, 2024. Location: No. 1661 Zhangdong Road, Zhangjiang Hi-Tech Park Pudong New District, Shanghai Chinaお知らせ • Mar 16MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2023 Results on Mar 27, 2024MicroPort CardioFlow Medtech Corporation announced that they will report fiscal year 2023 results on Mar 27, 2024お知らせ • Jan 08Microport Cardioflow Medtech Corporation Receives NMPA Approval for Registration Application of Anchorman LAAC SystemThe board of directors of the Company of MicroPort CardioFlow Medtech Corporation announced that, on January 5, 2024, MP CardioAdvent received the approval from the National Medical Products Administration of the People's Republic of China regarding the registration application for AnchorMan left atrial appendage closure system, the self-development product of MP CardioAdvent, which is also the only approved semi-closed type LAAC product in China so far. In addition, it completed the registration application of CE Mark in December 2023. AnchorMan LAAC System comprises a LAA closure and a delivery system, which is applicable for patients with nonvalvular atrial fibrillation with the CHA2DS2-VASC (a stroke risk assessment tool) score 2 and have contraindications in long-term oral anticoagulation therapy or still at risk of stroke after anticoagulation therapy. The major innovative designs of AnchorMan LAAC System include: the semi-closed structure formed by the 12 "3D folding" units and the frame combines the merits of an open and closed closure device, solving the clinical pain point that the access sheath of the traditional plug-in closure device must deep into the LAA, and achieving stable anchoring, the rounded and soft distal end could reduce damage to the LAA tissue; the dense NiTi alloy frame design allows very tight conformity to the anatomy of LAA and achieves better sealing performance; and two deployment models of advancement and unsheathe are available to provide more options for physicians. In addition, AnchorMan LAAC System is available in six closure device diameters ranging from 20 mm to 35 mm for a larger patient population. The NMPA registration approval of the AnchorMan LAAC System enables the Group to expand its business from heart valves to a new segment in the structural heart disease field with large patient population and fast growth rate, which will further expand the Company's revenue stream and enhance its comprehensive competitiveness.お知らせ • Oct 26MicroPort CardioFlow Medtech Corporation Completes Clinical Implantation Cases in EuropeThe board of directors of MicroPort CardioFlow Medtech Corporation announced that the Group's self-developed second-generation transcatheter aortic heart valve implantation ("TAVI") product, VitaFlow Liberty transcatheter aortic valve implantation system, has recently completed seven pre-market clinical implantation cases in Denmark and Ireland. All patients recovered well after the procedures. VitaFlow Liberty is the only self-developed TAVI product in China to conduct clinical trials in Europe, and is expected to become the first Chinese TAVI product to receive CE mark. As the world's first and only motorized retrievable TAVI system, after its registration approval by the China National Medical Products Administration in August 2021, VitaFlow Liberty has been successfully registered in Argentina, Colombia, Thailand and Russia and progressed its CE mark registration in good order. In its nearly 200 cases of overseas commercial applications, VitaFlow Liberty received high praises from overseas physicians for its excellent release stability, precise positioning, optimized perivalvular leakage prevention and hemodynamic performance. The successful advancement of VitaFlow Liberty's pre-market clinical trial will lay a solid foundation for its launch in markets recognizing the CE mark. The Group looks forward to the early approval for the CE mark registration of VitaFlow Liberty and its rapid subsequent commercialization in Europe to bring high quality and universally-accessible solutions to more TAVI patients around the world.お知らせ • Oct 17MicroPort CardioFlow Medtech Corporation Announces First Two Clinical Applications of Third-Generation TAVI ProductMicroPort CardioFlow Medtech Corporation announced that the third-generation transcatheter aortic heart valve implantation product independently developed by the Group ("Third-Generation TAVI Product") which is equipped with an upgraded retrievable steerable delivery system was successfully applied by the heart teams of Fuwai Hospital of the Chinese Academy of Medical Sciences and Shanxi Provincial Hospital of Cardiovascular Diseases to treat two patients with severe aortic stenosis. The patients are now recovering well with significant relief of related symptoms. The successful first-in-man applications of Third-Generation TAVI Product marked its entry into the clinical application phase and further enriched TAVI product offering to increase competitiveness. Originated from the Group's deep understanding of clinical needs and pain points, self-developed Third-Generation TAVI Product is an iteration of VitaFlow Liberty®, second-generation TAVI product which is now widely used in TAVI procedures. The delivery system of this product is upgraded with a highly innovative steerable function, which is designed to help cross the aortic arch and the native valve, facilitate the delivery process to achieve less tissue damage, enhance valve coaxiality during pre-positioning and release, make it easier to anchor in the appropriate position, further reduce the maneuver difficulty and increase positioning accuracy, thus improving the procedure success rate and enhancing the therapeutic effects. The unique spatial curvature is more in line with the human heart structure and is suitable for a variety of challenging anatomies. Meanwhile, the limit switch on the handle of the delivery system helps physicians to reduce the rate of intraoperative mishandling and further optimizes the procedure process. The first two successful clinical applications of the Third-Generation TAVI Product is another important milestone of the Group's comprehensive deployment in the field of structural heart disease, and a manifestation of solid technical reserves and innovative research & development capabilities in the field of structural heart diseases. The product impresses physicians with its excellent ease-of-use, more accurate positioning and improved procedure efficiency. look forward to the launch of the Third-Generation TAVI Product as soon as possible to treat more patients with aortic valve disease.お知らせ • Aug 30+ 2 more updatesMicroPort Cardioflow Medtech Corporation Announces Executive ChangesMicroPort CardioFlow Medtech Corporation announced that with effect from August 29, 2023: Mr. Chen Guoming has resigned as general manager of MP CardioFlow and re-designated from an executive Director to a non-executive Director, and has been appointed as the Chairman, the chairman of Nomination Committee, a member of Remuneration Committee, an Authorized Representative and the chairman of MP CardioFlow; and Mr. Jeffrey R Lindstrom has been appointed as the general manager of MP CardioFlow. Mr. Chen, aged 38, joined the Group as a vice president on September 1, 2016 and was mainly responsible for research and development ("R&D") since then and participating in the management and strategic development of Group. He served as an executive Director, President and director and general manager of MP CardioFlow from September 29, 2020 to August 29, 2023. Mr. Chen focused on research and development, clinical application and supply chain management of devices in the field of valves for more than 10 years. Before joining the Company in September 2016, Mr. Chen joined the group of MicroPort Scientific Corporation in March 2010 and worked as senior R&D manager at Shanghai MicroPort Medical (Group) Co. Ltd. from March 2010 to August 2016. Mr. Chen obtained a bachelor's degree in engineering mechanics from Shanghai Jiao Tong University in China in June 2007 and a master's degree in mechatronics engineering from Shanghai Jiao Tong University in China in March 2010. He is also the inventor or a co-inventor of over 100 invention patents in China and overseas as of the date of this announcement. Mr. Lindstrom, aged 57, joined Group in January 2022 as the vice president (R&D) of Company. He has over 25 years R&D experience in the minimally invasive interventional medical device industry. Prior to joining the Group, he served as senior director of engineering in Edwards Lifesciences Corporation (New York Stock Exchange ticker symbol: EW) since 2012, where he was responsible for developing the R&D strategy, directing and managing the R&D activities, overseeing the full product development lifecycle, leading the development and commercialization of the electro-mechanical transcatheter heart valve system and leading the development and clinical evaluation of the embolic protection system. From 2008 to 2012, he served as R&D director of The Spectranetics Corporation. From 1998 to 2006, he served as R&D manager of Abbott Vascular (formerly known as Guidant Corporation). Mr. Lindstrom obtained his bachelor's degree in chemical engineering from Illinois Institute of Technology in the United States in 1996. He also obtained the certificate of general management from UCLA Anderson School of Management in the United States in 2016. He owns six patents relating to the cardiovascular medical devices.お知らせ • Aug 18MicroPort CardioFlow Medtech Corporation to Report First Half, 2023 Results on Aug 29, 2023MicroPort CardioFlow Medtech Corporation announced that they will report first half, 2023 results on Aug 29, 2023業績と収益の成長予測OTCPK:MROP.F - アナリストの将来予測と過去の財務データ ( )CNY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202677712416N/A212/31/2025573-47-105-100212/31/2024454-162-70-4526/30/2024383-349-182-167N/A3/31/2024360-410-210-187N/A12/31/2023336-472-237-207N/A9/30/2023319-491-250-216N/A6/30/2023303-511-263-226N/A3/31/2023277-483-247-204N/A12/31/2022251-454-232-183N/A9/30/2022245-345-270-191N/A6/30/2022239-236-309-199N/A3/31/2022220-209-290-180N/A12/31/2021201-183-270-162N/A9/30/2021176-265N/AN/AN/A6/30/2021151-346N/AN/AN/A3/31/2021128-372N/AN/AN/A12/31/2020104-398-168-110N/A12/31/201922-145-191-143N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: MROP.Fは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 2.6% ) よりも高い成長率であると考えられます。収益対市場: MROP.F今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: MROP.F今後 3 年以内に収益を上げることが予想されます。収益対市場: MROP.Fの収益 ( 24.7% ) US市場 ( 11.7% ) よりも速いペースで成長すると予測されています。高い収益成長: MROP.Fの収益 ( 24.7% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: MROP.Fの 自己資本利益率 は、3年後には低くなると予測されています ( 1.7 %)。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/12/22 23:29終値2024/09/25 00:00収益2024/06/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MicroPort CardioFlow Medtech Corporation 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Harry HeCGS Internationalnull nullChina International Capital Corporation LimitedBo YuChina International Capital Corporation Limited3 その他のアナリストを表示
お知らせ • Mar 31MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 04, 2026MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 04, 2026. Location: no.501 niudun road, pudong new district, shanghai, China
お知らせ • Mar 18MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2025 Results on Mar 30, 2026MicroPort CardioFlow Medtech Corporation announced that they will report fiscal year 2025 results on Mar 30, 2026
お知らせ • Aug 15MicroPort CardioFlow Medtech Corporation to Report First Half, 2025 Results on Aug 28, 2025MicroPort CardioFlow Medtech Corporation announced that they will report first half, 2025 results on Aug 28, 2025
お知らせ • Jun 27MicroPort CardioFlow Medtech Corporation Announces Board Changes, Effective June 27, 2025MicroPort CardioFlow Medtech Corporation announced that Dr. Ding Jiandong (Dr. Ding) retired as an independent non-executive Director with effect from the conclusion of the AGM and did not offer himself for re-election at the AGM as disclosed in the Circular. Accordingly, Dr. Ding ceased to act as a member of each of the audit committee (the Audit Committee) and nomination committee of the Company (the Nomination Committee) with effect from the conclusion of the AGM. Dr. Ding has confirmed that he has no disagreement with the Board and there is no matter relating to his retirement that needs to be brought to the attention of the Shareholders or the Stock Exchange. The Board announced that Dr. Hu Bingshan (Dr. Hu) has been appointed as an independent non-executive Director and a member of each of the Audit Committee and Nomination Committee, with effect from June 27, 2025 following the retirement of Dr. Ding. The biographical details of Dr. Hu are set out: Dr. Hu, aged 43, has successively served as associate professor and professor at the University of Shanghai for Science and Technology since November 2016. His main research field is rehabilitation and nursing robotics. From October 2010 to November 2016, Dr. Hu worked as a space robotics systems engineer at the Shanghai Aerospace System Engineering Institute in the China Aerospace Science and Technology Corporation. In 2015, he also served as a visiting scholar at the University of Hamburg in Germany. Dr. Hu serves as a committee member for the Sports Health and Industry Promotion Committee of China Association of Rehabilitation Medicine and other relevant academic organizations. He received the First Prize and the Second Prize of Science and Technology from the China Association of Rehabilitation Medicine in October 2023 and in September 2024, respectively. Dr. Hu has published more than 50 papers in internationally recognized journals or academic conferences. He is also an inventor or co-inventor of more than 70 Chinese and overseas patents. Dr. Hu received his bachelor's degree in electrical engineering and automation and his master's degree in power electronics and electric drives from Harbin University of Science and Technology in July 2003 and April 2006, respectively, and obtained his Ph.D. in mechatronic engineering from Shanghai Jiao Tong University in December 2010. Dr. Hu shall only hold office until the next annual general meeting of the Company and will be eligible for and subject to re-election at such meeting in accordance with the articles of association of the Company.
お知らせ • Mar 28MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 27, 2025MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 27, 2025. Location: no. 1661 zhangdong road, zhangjiang hi-tech park, pudong new district, shanghai China
お知らせ • Mar 17MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2024 Results on Mar 27, 2025MicroPort CardioFlow Medtech Corporation announced that they will report fiscal year 2024 results at 4:00 PM, China Standard Time on Mar 27, 2025
お知らせ • Aug 15MicroPort CardioFlow Medtech Corporation to Report First Half, 2024 Results on Aug 28, 2024MicroPort CardioFlow Medtech Corporation announced that they will report first half, 2024 results on Aug 28, 2024
お知らせ • Mar 29MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 26, 2024MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 26, 2024. Location: No. 1661 Zhangdong Road, Zhangjiang Hi-Tech Park Pudong New District, Shanghai China
お知らせ • Mar 16MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2023 Results on Mar 27, 2024MicroPort CardioFlow Medtech Corporation announced that they will report fiscal year 2023 results on Mar 27, 2024
お知らせ • Jan 08Microport Cardioflow Medtech Corporation Receives NMPA Approval for Registration Application of Anchorman LAAC SystemThe board of directors of the Company of MicroPort CardioFlow Medtech Corporation announced that, on January 5, 2024, MP CardioAdvent received the approval from the National Medical Products Administration of the People's Republic of China regarding the registration application for AnchorMan left atrial appendage closure system, the self-development product of MP CardioAdvent, which is also the only approved semi-closed type LAAC product in China so far. In addition, it completed the registration application of CE Mark in December 2023. AnchorMan LAAC System comprises a LAA closure and a delivery system, which is applicable for patients with nonvalvular atrial fibrillation with the CHA2DS2-VASC (a stroke risk assessment tool) score 2 and have contraindications in long-term oral anticoagulation therapy or still at risk of stroke after anticoagulation therapy. The major innovative designs of AnchorMan LAAC System include: the semi-closed structure formed by the 12 "3D folding" units and the frame combines the merits of an open and closed closure device, solving the clinical pain point that the access sheath of the traditional plug-in closure device must deep into the LAA, and achieving stable anchoring, the rounded and soft distal end could reduce damage to the LAA tissue; the dense NiTi alloy frame design allows very tight conformity to the anatomy of LAA and achieves better sealing performance; and two deployment models of advancement and unsheathe are available to provide more options for physicians. In addition, AnchorMan LAAC System is available in six closure device diameters ranging from 20 mm to 35 mm for a larger patient population. The NMPA registration approval of the AnchorMan LAAC System enables the Group to expand its business from heart valves to a new segment in the structural heart disease field with large patient population and fast growth rate, which will further expand the Company's revenue stream and enhance its comprehensive competitiveness.
お知らせ • Oct 26MicroPort CardioFlow Medtech Corporation Completes Clinical Implantation Cases in EuropeThe board of directors of MicroPort CardioFlow Medtech Corporation announced that the Group's self-developed second-generation transcatheter aortic heart valve implantation ("TAVI") product, VitaFlow Liberty transcatheter aortic valve implantation system, has recently completed seven pre-market clinical implantation cases in Denmark and Ireland. All patients recovered well after the procedures. VitaFlow Liberty is the only self-developed TAVI product in China to conduct clinical trials in Europe, and is expected to become the first Chinese TAVI product to receive CE mark. As the world's first and only motorized retrievable TAVI system, after its registration approval by the China National Medical Products Administration in August 2021, VitaFlow Liberty has been successfully registered in Argentina, Colombia, Thailand and Russia and progressed its CE mark registration in good order. In its nearly 200 cases of overseas commercial applications, VitaFlow Liberty received high praises from overseas physicians for its excellent release stability, precise positioning, optimized perivalvular leakage prevention and hemodynamic performance. The successful advancement of VitaFlow Liberty's pre-market clinical trial will lay a solid foundation for its launch in markets recognizing the CE mark. The Group looks forward to the early approval for the CE mark registration of VitaFlow Liberty and its rapid subsequent commercialization in Europe to bring high quality and universally-accessible solutions to more TAVI patients around the world.
お知らせ • Oct 17MicroPort CardioFlow Medtech Corporation Announces First Two Clinical Applications of Third-Generation TAVI ProductMicroPort CardioFlow Medtech Corporation announced that the third-generation transcatheter aortic heart valve implantation product independently developed by the Group ("Third-Generation TAVI Product") which is equipped with an upgraded retrievable steerable delivery system was successfully applied by the heart teams of Fuwai Hospital of the Chinese Academy of Medical Sciences and Shanxi Provincial Hospital of Cardiovascular Diseases to treat two patients with severe aortic stenosis. The patients are now recovering well with significant relief of related symptoms. The successful first-in-man applications of Third-Generation TAVI Product marked its entry into the clinical application phase and further enriched TAVI product offering to increase competitiveness. Originated from the Group's deep understanding of clinical needs and pain points, self-developed Third-Generation TAVI Product is an iteration of VitaFlow Liberty®, second-generation TAVI product which is now widely used in TAVI procedures. The delivery system of this product is upgraded with a highly innovative steerable function, which is designed to help cross the aortic arch and the native valve, facilitate the delivery process to achieve less tissue damage, enhance valve coaxiality during pre-positioning and release, make it easier to anchor in the appropriate position, further reduce the maneuver difficulty and increase positioning accuracy, thus improving the procedure success rate and enhancing the therapeutic effects. The unique spatial curvature is more in line with the human heart structure and is suitable for a variety of challenging anatomies. Meanwhile, the limit switch on the handle of the delivery system helps physicians to reduce the rate of intraoperative mishandling and further optimizes the procedure process. The first two successful clinical applications of the Third-Generation TAVI Product is another important milestone of the Group's comprehensive deployment in the field of structural heart disease, and a manifestation of solid technical reserves and innovative research & development capabilities in the field of structural heart diseases. The product impresses physicians with its excellent ease-of-use, more accurate positioning and improved procedure efficiency. look forward to the launch of the Third-Generation TAVI Product as soon as possible to treat more patients with aortic valve disease.
お知らせ • Aug 30+ 2 more updatesMicroPort Cardioflow Medtech Corporation Announces Executive ChangesMicroPort CardioFlow Medtech Corporation announced that with effect from August 29, 2023: Mr. Chen Guoming has resigned as general manager of MP CardioFlow and re-designated from an executive Director to a non-executive Director, and has been appointed as the Chairman, the chairman of Nomination Committee, a member of Remuneration Committee, an Authorized Representative and the chairman of MP CardioFlow; and Mr. Jeffrey R Lindstrom has been appointed as the general manager of MP CardioFlow. Mr. Chen, aged 38, joined the Group as a vice president on September 1, 2016 and was mainly responsible for research and development ("R&D") since then and participating in the management and strategic development of Group. He served as an executive Director, President and director and general manager of MP CardioFlow from September 29, 2020 to August 29, 2023. Mr. Chen focused on research and development, clinical application and supply chain management of devices in the field of valves for more than 10 years. Before joining the Company in September 2016, Mr. Chen joined the group of MicroPort Scientific Corporation in March 2010 and worked as senior R&D manager at Shanghai MicroPort Medical (Group) Co. Ltd. from March 2010 to August 2016. Mr. Chen obtained a bachelor's degree in engineering mechanics from Shanghai Jiao Tong University in China in June 2007 and a master's degree in mechatronics engineering from Shanghai Jiao Tong University in China in March 2010. He is also the inventor or a co-inventor of over 100 invention patents in China and overseas as of the date of this announcement. Mr. Lindstrom, aged 57, joined Group in January 2022 as the vice president (R&D) of Company. He has over 25 years R&D experience in the minimally invasive interventional medical device industry. Prior to joining the Group, he served as senior director of engineering in Edwards Lifesciences Corporation (New York Stock Exchange ticker symbol: EW) since 2012, where he was responsible for developing the R&D strategy, directing and managing the R&D activities, overseeing the full product development lifecycle, leading the development and commercialization of the electro-mechanical transcatheter heart valve system and leading the development and clinical evaluation of the embolic protection system. From 2008 to 2012, he served as R&D director of The Spectranetics Corporation. From 1998 to 2006, he served as R&D manager of Abbott Vascular (formerly known as Guidant Corporation). Mr. Lindstrom obtained his bachelor's degree in chemical engineering from Illinois Institute of Technology in the United States in 1996. He also obtained the certificate of general management from UCLA Anderson School of Management in the United States in 2016. He owns six patents relating to the cardiovascular medical devices.
お知らせ • Aug 18MicroPort CardioFlow Medtech Corporation to Report First Half, 2023 Results on Aug 29, 2023MicroPort CardioFlow Medtech Corporation announced that they will report first half, 2023 results on Aug 29, 2023